-+ 0.00%
-+ 0.00%
-+ 0.00%
Senapali was approved by the European Union to take a key step in global commercialization, and the accelerated implementation of innovative value became the key to Yingpai Pharmaceutical-B (07630) allocation
Share
Listen to the news

On November 17, Yingpai Pharmaceutical-B (07630) issued an announcement announcing that the innovative drug Senapali (Chinese product name: Pai Shuning®, overseas product name: Sepalna®) has officially obtained a final decision from the European Commission (EC) to approve it for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer.

Since then, senapalil has become the first PARP inhibitor for first-line maintenance treatment of advanced ovarian cancer in China to be approved and marketed by the European Union, marking another breakthrough for domestically produced innovative drugs targeting ovarian cancer in the European market.

As a core product with BIC potential under Yingpai Pharmaceutical, the world's first application for the marketing of Senapali was officially approved in China in January of last year, entered medical insurance in December of that year, and officially reimbursed in January 2026. As a result, the drug became the “fastest player from marketing to medical insurance” in the PARP inhibitor family. Today, Senapali is on the market in many countries and regions, including China and Europe, which means that this “synthetic death star” has begun a real global commercialization process.

In the secondary market, Yingpai Pharmaceutical's rise in November this year is undoubtedly the most tangible reflection of investors' high recognition of the company's value and expectations.

The Zhitong Finance App observed that since November, Yingpai Pharmaceutical's stock price has experienced a clear wave of rising prices. The biggest increase in the company's stock price in the month reached 40.27%; on November 17, the day of the announcement, Yingpai Pharmaceutical's intraday stock price rose to 27.83%.

From hard-core innovation to global monetization, as Senapali steadily enters the stage of global hematopoiesis, the drug is expected to bring clear profits to Yingpai and contribute stable recurring cash flow in the future, laying a solid foundation for the continued implementation of the company's subsequent innovation pipeline and the realization of platform value.

Successfully opened up the EU market and accelerated global commercialization

The reason why investors in the secondary market began allocating before Yingpai Pharmaceutical's official announcement was issued is that the registration and commercialization process of Senapali in the European Union is essentially a process of gradually increasing certainty.

After Senapali's EU marketing license application (MAA) for first-line maintenance treatment of adults with advanced ovarian cancer in Europe was officially accepted by the EMA in August 2025, Yingpai Pharmaceutical intensively promoted the international commercialization of the drug.

In July of this year, the company reached an exclusive licensing agreement with global specialty pharmaceutical company Pharmanovia for “high consideration, high milestone, and high share”, granting it exclusive production, R&D and commercialization rights in a total of 66 countries and regions, including Europe, the Middle East, North Africa, Australia and New Zealand. Relying on Pharmanovia's mature overseas medical, regulatory, market access and commercialization system, we continue to enhance Senapali's global market accessibility.

For Yingpai Pharmaceutical, the transaction has strong commercial value in return.

In addition to receiving a maximum total of 423.5 million euros, including down payment, registration milestones, and commercialization milestones in the sales ladder, the company will also receive subsequent payments from Pharmanovia for tiered sales royalties based on the highest to middle 20-digit ratio based on the net sales value of products within the partner region.

It is worth mentioning that at the time of the cooperation with Pharmanovia, Senapali's EU registration was still in the EMA acceptance phase. At this point in time, Pharmanovia chose to reach this “high price, high milestone, and high share” exclusive licensing agreement, which fully reflects the high recognition of Senapali's molecular quality, clinical data and intellectual property rights, and global commercialization potential by international peers.

In fact, it is the drug's excellent clinical data that supports the British, partners, and secondary market expectations for approval of senapalil. Earlier, the key phase III FLAMES study showed that in the pre-set mid-term analysis, the median progression-free survival in the senapali group was not achieved, while the placebo group was 13.6 months; compared with placebo, senapalil reduced the risk of disease progression or death by 57%, and BRCA testing was not required, and the whole population benefited the same.

This EMA review of Senapali is mainly based on the above research. On September 18 this year, the company announced that it had received a positive opinion from the EMA Human Medicines Committee (CHMP), recommending approval of Senapa for first-line maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. This positive opinion directly points to the final review by the European Commission (EC), and ultimately contributed to Senapali's successful approval in the EU.

Continue to explore the commercialization potential of core varieties

From a market perspective, according to the latest statistics from QYResearch, the global PARP inhibitor market sales in 2025 will be approximately US$5.995 billion. Among them, AstraZeneca's olapalide is the only one, with sales reaching US$3.279 billion in 2025; in China, 5 PARP inhibitors are already competing on the same stage.

The reason why senapalil has the ambition to challenge the global market stems from the fact that the drug is an extremely scarce variety in the industry with potentially the best efficacy in the same category, significant safety differentiation advantages, and a “whole group” market positioning.

According to the Zhitong Finance App, although the indications of olapalil have expanded to include breast cancer, prostate cancer, etc., GlobalData previously predicted that in 2027 sales would reach 4 billion US dollars, accounting for 68% of the global PARP market, its core label is still limited to people with BRCA mutations, not “the whole population.” Another GSK Nirapali, which has a scarce label of “all people”, has a market forecast sales volume of 1.6 billion US dollars in 2027, which is enough to show the huge commercial potential of “all people to benefit” in this field.

At the same time, data from the Phase III FLAMES study showed that the efficacy of senapalil was remarkable. Its HR value was only 0.43, which showed a very advantageous risk ratio. Not only was it superior to the domestic registration data of similar competitors across trials, but its HR value was also highly consistent in the three subgroups. Compared with other competitors, it was less affected by the homologous recombination status, showing potential best-in-class efficacy advantages.

In addition to having a scarce “all-population” positioning and best-in-class curative potential, another core reason why Senapali is expected to overtake a corner is its safety characteristics, which have significant differentiating advantages.

For previously approved PARP1/2 inhibitors, hematologic toxicity is an unavoidable pain point. In the PRIMA study mentioned above, the incidence of grade 3/4 thrombocytopenia was as high as 41%, and was accompanied by non-hematologic toxicity such as gastrointestinal reactions, resulting in a significant proportion of patients requiring dose reduction or even discontinuation of treatment.

Thanks to its unique molecular structure, which brings excellent target selectivity and a broad safety window, FLAMES research data showed that senapalil mainly had grade 1/2 of non-hematological adverse events (AEs), less than other PARP inhibitors already on the market in terms of quantity and grade, and the incidence of drug discontinuation due to adverse events was only 4.4% (more than 10% for all other competitive products). At the same time, compared with the higher incidence of grade 3 hypertension with nirapalil, no risk of hypertension was observed with senapalil, and the incidence of gastrointestinal toxicity was lower than that of similar competitors, which can significantly improve medication compliance.

Since it was approved for domestic listing in January last year, Senapali has gone through its first year of commercialization. According to the 26H1 financial report, Senapali's sales revenue during the period reached 70.35 million yuan, a year-on-year increase of 872.8%, which led to a 316.8% year-on-year increase in the company's current revenue. The drug's BIC potential and commercialization potential have apparently been initially verified in the domestic market.

In addition, Yingpai Pharmaceutical is also promoting the development of a combination of PARP1, ATR inhibitors, and senapalil to address clinical pain points in the treatment of solid tumors after resistance to PARP inhibitors, and further raise the commercial ceiling of senapalil.

Accelerate differentiated innovation, and the value of the platform has been further verified

In fact, as a platform-based Biotech with significant differentiated innovation value, its underlying logic and value core mainly stem from the integrated independent R&D innovation platform and the company's deep layout in the field of synthetic lethality.

According to the Zhitong Finance App, in recent years, the company has relied on science-driven target selection and unique innovative technology platforms (including ADC connector-payload platforms and PROTAC target degradant platforms) to achieve a seamless connection from early detection to clinical stage development.

Today, with the technical support of the innovative platform, the company has carried out an in-depth and comprehensive synthetic lethal circuit layout and built a rich innovative pipeline of drug candidates. Yingpai Pharmaceutical is not only one of the few innovative pharmaceutical companies in the world that also has commercialized PARP1/2 inhibitors and clinical-stage PARP1 selective inhibitors. The company also thoroughly covers multiple targets including ATR, WEE1, ATM, USP1, CHK1/2, and DHX9. The scarcity of innovative assets can be seen.

Take the development of next-generation PARP1 selective inhibitors as an example. Their advantages over PARP2 inhibitors can reduce hematological toxicity while retaining efficacy, opening up a wider treatment window and more flexible collaboration space, and have huge indications and market expansion potential.

With the support of innovative platform technology, Yingpai Pharmaceutical is at the forefront of the development of next-generation PARP1 selective inhibitors in the world. The impenetrable IMP1734 and the brain-penetrating IMP1707 developed were granted to multinational giant EIKON as early as 2023, leading to a BD transaction with a potential total value of nearly 1 billion US dollars, fully verifying its innovation potential and global commercialization value.

In fact, in addition to PARP, targets such as ATR, PRMT5, and USP1 have also shown potential for drug development in recent years, and each has a market space of several billion dollars. Furthermore, treatment matrices that are jointly constructed with multiple synthetic lethal targets also have market potential of tens of billions of dollars.

In this market context, Yingpai Pharmaceutical's certainty in global commercialization and differentiated original research innovation continues to increase, and the company will also open up more room for valuation imagination through multiple potential FIC/BIC products in the pipeline.

epilogue

In the current environment, an important sign that an innovative pharmaceutical company has high investment certainty is to switch the company's cash cycle pillar from financing cash flow to net operating cash flow. This requires pharmaceutical companies to have a “phenomenal” cash cow product to support it. Today, the core product Senapali has been approved for listing in China, the European Union and other countries and regions, providing key conditions for the steady growth of the company's internal value.

Furthermore, based on recognition of its “innovation-value realization” positive cycle value, Yingpai Pharmaceutical also announced a repurchase plan on November 4. It plans to repurchase the company's shares for no more than HK$100 million, and the company may further repurchase H shares within the scope of the repurchase authorization granted by the shareholders' meeting depending on market conditions. While using “real money” to give back to investors, Yingpai Pharmaceutical expressed strong confidence in the company's future development to the market.

As Yingpai Pharmaceutical officially enters a new stage of commercial hematopoiesis, in the future, with abundant cash flow support from Senapali's global investment, it is expected to accelerate the construction of its own differentiated innovation and accelerate the transition to Biopharma in systematic competition in various fields such as global R&D, overseas registration, and international commercialization.


Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending